Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2013 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Interest & Investment Income of $2000.0 for Q1 2021, down 99.51% year-over-year from $405000.0 in Q1 2020, and little changed quarter-over-quarter from $2000.0 in Q4 2020.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2013 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $2000.0 for Q1 2021.
- In Q1 2021, Interest & Investment Income fell 99.51% year-over-year to $2000.0; the TTM figure through Mar 2021 stood at $636000.0 (down 61.41% YoY), while the FY2020 annual figure was $1.0 million, down 38.34% from the prior year.
- Interest & Investment Income for Q1 2021 stood at $2000.0, roughly flat from $2000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $442000.0 in Q1 2019, with the low at $2000.0 in Q4 2020.
- The 3-year median for Interest & Investment Income is $399000.0 (2019), against an average of $302888.9.
- Peak annual rise in Interest & Investment Income reached 8.37% in 2020, while the deepest fall reached 99.51% in 2020.
- Lineage Cell Therapeutics' Interest & Investment Income stood at $407000.0 in 2019, then sank by 99.51% to $2000.0 in 2020, then changed by 0.0% to $2000.0 in 2021.
- Business Quant data shows LCTX's Interest & Investment Income at $2000.0 in Q1 2021, $2000.0 in Q4 2020, and $252000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 378,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 378,000.00 |
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 478,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Sep 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 463,000.00 |
| Mar 31, 2024 | 462,000.00 |
| Dec 31, 2023 | 404,000.00 |
| Sep 30, 2023 | 433,000.00 |
| Jun 30, 2023 | 382,000.00 |
| Mar 31, 2023 | 410,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 252,000.00 |
| Jun 30, 2020 | 380,000.00 |
| Mar 31, 2020 | 405,000.00 |
| Dec 31, 2019 | 407,000.00 |